Zymergen ($ZY) Investor Settlement
Zymergen has reached a settlement with $ZY investors to resolve claims that it misled them in connection with its 2021 IPO by overstating its product readiness, commercial potential, and financial outlook.
Outline:
Zymergen went public in April 2021 while promoting Hyaline as commercially viable and emphasizing strong demand and near-term growth. Months later, the company disclosed Hyaline had unexpected performance issues and that commercial revenue would be delayed. After these disclosures, $ZY collapsed, including a 68% drop on August 4, 2021, and investor claims followed. Zymergen later reached a tentative settlement to resolve those allegations.
Timeline:
April 2021: Zymergen completed its IPO, raising over $500 million.
August 3, 2021: Zymergen disclosed that Hyaline was underperforming and commercial revenue would be delayed.
August 4, 2021: $ZY plunged 68%, wiping out more than $2.5 billion in market value.
August 2021: CEO Josh Hoffman resigned amid the fallout.
March 2022: Investors filed suit alleging IPO-related misstatements.
December 2025: Zymergen reached a tentative settlement to resolve all claims.
Background:
Ahead of its IPO, Zymergen promoted Hyaline, a film material for electronics, as its lead commercial product and portrayed itself as a key innovator in synthetic biology. Its public messaging emphasized product readiness, strong demand, and near-term revenue growth.
Within months of going public, Zymergen disclosed that Hyaline was underperforming and that commercial revenue would be delayed, and it withdrew financial guidance. The description states the stock collapsed, including a 68% drop on August 4, 2021, and a broader decline of more than 70%.
Shareholders allege these outcomes contradicted the company’s earlier picture of Hyaline’s performance and market demand. The claims contend Zymergen overstated its technology, customer pipeline, and the viability of its business model in connection with the IPO.
What Can Investors Expect Now?
Zymergen has reached a settlement with $ZY investors to resolve claims tied to alleged misstatements about Hyaline and the company’s commercial and financial outlook around its 2021 IPO.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Frequently Asked Questions
All persons and entities that purchased or otherwise acquired Zymergen common stock pursuant and/or traceable to the Registration Statement issued in connection with Zymergen’s April 2021 IPO.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.